Biotech Growth Trust

The Biotech Growth Trust PLC (“the Company”)

Compliance with Market Abuse Regulation

29 April 2022

The Company confirms that:

a)         all inside information which the Directors and Company may have had has been notified to a Regulated Information Service (“RIS”);

b)         the Company’s net asset value per share is calculated and announced through a RIS on a daily basis;

c)         the Company has no reason to believe that there will be any material difference between the net asset value per share as at close of business on Thursday 31 March 2022, which was announced on Friday, 1 April 2022, and the financial information to be published in the announcement of its results for the year ended 31 March 2022.

The Company is, therefore, not prohibited from dealing in its own securities during the closed period, as defined by the UK Market Abuse Regulation, which will end on the date of the publication of its results for the year ended 31 March 2022, expected to be on or after Wednesday, 1 June 2022. 

-ENDS-

For further information please contact:

Katherine Manson      Frostrow Capital LLP - 020 3 709 8734